Data / Form D filings / Linnaeus Therapeutics, Inc.
Linnaeus Therapeutics, Inc.: Form D filings
Linnaeus Therapeutics, Inc., a biotechnology company in Haddonfield, NJ, filed 11 Form D notices with the SEC between 2018 and 2026. The latest, on April 2, 2026, reports $5 million sold of a $10 million offering to 26 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 30 WASHINGTON AVENUE, SUITE F, Haddonfield, NJ, 08033
- Phone
- (856) 433-1500
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1752026
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 2, 2026 | Amendment | $10,000,000 | $4,992,000 | $5,008,000 | 26 | Feb 17, 2026 | sec.gov |
| Mar 31, 2026 | Amendment | $10,000,000 | $4,892,000 | $5,108,000 | 26 | Feb 17, 2026 | sec.gov |
| Mar 13, 2026 | Amendment | $10,000,000 | $4,792,000 | $5,208,000 | 25 | Feb 17, 2026 | sec.gov |
| Feb 27, 2026 | New notice | $10,000,000 | $4,475,000 | $5,525,000 | 19 | Feb 17, 2026 | sec.gov |
| Aug 22, 2025 | New notice | $10,000,000 | $1,275,000 | $8,725,000 | 3 | Aug 19, 2025 | sec.gov |
| Dec 26, 2024 | Amendment | $6,860,000 | $5,824,155 | $1,035,845 | 12 | Aug 12, 2024 | sec.gov |
| Aug 12, 2024 | New notice | $3,920,000 | $1,628,398 | $2,291,602 | 6 | Aug 12, 2024 | sec.gov |
| Jan 26, 2023 | New notice | $3,088,234 | $3,088,234 | 8 | Jan 24, 2023 | sec.gov | |
| Aug 24, 2021 | New notice | $4,344,675 | $4,344,675 | 15 | Aug 9, 2021 | sec.gov | |
| Feb 8, 2019 | New notice | Indefinite | $2,160,000 | 3 | Jan 23, 2019 | sec.gov | |
| Sep 7, 2018 | New notice | Indefinite | $2,160,000 | 4 | Aug 27, 2018 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Patrick Mooney | Executive Officer, Director | |
| James Demetriades | Director | |
| Michael Poisel | Director | |
| Chris Arendt | Director | |
| Todd Thomson | Director | |
| John Lepping | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Mar 30, 2026 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Linnaeus Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.